A cost-utility study of the use of pregabalin added to usual care in refractory neuropathic pain patients in a Swedish setting

Journal of Medical Economics

Volumn 15, Issue 6, 2012, Pages 1097-1109

  Prettyjohns, Matthew ^a   Sandelin, Rebecka ^b   Lister, Steven ^a   Norrefalk, Jan Rickard ^c  

^a Cardiff Research Consortium   (United Kingdom)

^b PFIZER INC   (United States)

^c KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Cost utility; Pregabalin; Refractory neuropathic pain; Sweden

Indexed keywords

PREGABALIN;

ARTICLE; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DRUG COST; DRUG WITHDRAWAL; HUMAN; NEUROPATHIC PAIN; SENSITIVITY ANALYSIS; SWEDEN; UNSPECIFIED SIDE EFFECT;

ANALGESICS; CLINICAL TRIALS AS TOPIC; COST-BENEFIT ANALYSIS; GAMMA-AMINOBUTYRIC ACID; HEALTH SERVICES; HUMANS; MODELS, ECONOMETRIC; NEURALGIA; PAIN MANAGEMENT; QUALITY OF LIFE; QUALITY-ADJUSTED LIFE YEARS; SWEDEN; TIME FACTORS;

EID: 84869820585     PISSN: 13696998     EISSN: 1941837X     Source Type: Journal    
DOI: 10.3111/13696998.2012.704458     Document Type: Article

References (43)

1. Treede RD, Jensen TS, Campbell JN, et al. Redefinition of neuropathic pain and a grading system for clinical use: consensus statement on clinical and research diagnostic criteria. Neurology 2008;70:1630-5
2. HaanpääML, Backonja MM, Bennett MI, et al. Assessment of neuropathic pain in primary care. Am J Med 2009;122:S13-21
3. Bouhassira D, Lanteri-Minet M, Attal N, et al. Prevalence of chronic pain with neuropathic characteristics in the general population. Pain 2008;136:380-7
4. Gustorff B, Dorner T, Likar R, et al. Prevalence of self-reported neuropathic pain and impact on quality of life: a prospective representative survey. Acta Anaesthesiol Scand 2008;52:132-6
5. Torrance N, Smith BH, Bennett MI, et al. The epidemiology of chronic pain of predominantly neuropathic origin. Results from a general population survey. J Pain 2006;7:281-9
6. Information från Läkemedelsverket. Farmakologisk behandling av neuropatisk smärta.-Bakgrundsdokumentation. Medical Product Agency 2007;6:1-41
7. SBU. The Swedish council on technology assessment in health care. Methods of treating chronic pain. A systematic review [in Swedish]. Stockholm: Statens beredning fór medicinsk utvärdering (SBU), SBU-rapport nr 177/1, 2006
8. Brattberg G, Thorslund M, Wikman A. The prevalence of pain in a general population. The results of a postal survey in a county of Sweden. Pain 1989;5:215-22
9. SoS-rapport 1994:4 Behandling av lå ngvarig smärta. Socialstyrelsen ISBN 91-38-11366-X, ISSN 1100-2808. http://www.socialstyrelsen. se/ publikationer1994/1994-3-4
10. Dworkin RH. An overview of neuropathic pain: syndromes, symptoms, signs and several mechanisms. Clin J Pain 2002;18:343-9
11. Jensen M, Chodroff M, Dworkin R. The impact of neuropathic pain on healthrelated quality of life: review and implications. Neurology 2007;68:1178-82
12. Meyer-Rosberg K, Kvarnström A, Kinnman E, et al. Peripheral neuropathic pain-a multidimensional burden for patients. Eur J Pain 2001;5:379-89
13. Dworkin RH, Malone DC, Panarites CJ, et al. Impact of postherpetic neuralgia and painful diabetic peripheral neuropathy on health care costs. J Pain 2010;11:2010
14. Freynhagen R, Strojek K, Griesing T, et al. Efficacy of pregabalin in neuropathic pain evaluated in a 12-week, randomised, double-blind, multicentre, placebo-controlled trial of flexible- and fixed-dose regimens. Pain 2005;115:254-63
15. Stacey BR, Dworkin RH, Murphy K, et al. Pregabalin in the treatment of refractory neuropathic pain: results of a 15-month open-label trial. Pain Med 2008;9:1202-8
16. Douglas E, Forbes RD, Smith SC, et al. An audit of pregabalin for refractory neuropathic pain. Poster presented at British Pain Society, April 2007, Liverpool
17. Allen S. Pregabalin - is it any better than gabapentin? Poster presented at 2005 World Congress of Pain, Sydney, Australia
18. Freynhagen R, Grond S, Schuepfer G, et al. Efficacy and safety of pregabalin in treatment refractory patients with various neuropathic pain entities in clinical routine. Int J Clin Pract 2007;61:1989-96
19. Toth C. Substitution of gabapentin therapy with pregabalin therapy in neuropathic pain due to peripheral neuropathy. Pain Med 2010;11:456-65
20. Rosenstock J, Tuchman M, LaMoreaux L, et al. Pregabalin for the treatment of painful diabetic peripheral neuropathy: a double-blind, placebo-controlled trial. Pain 2004;110:628-38
21. Blommel ML, Blommel AL. Pregabalin: an antiepileptic agent useful for neuropathic pain: pharmacokinetics. Am J Health-Syst Pharm 2007;64:1475-82
22. Läkemedelsverket. Farmakologisk behandling vid neuropatisk smärta- Behandlingsrekommendation och bakgrundsdokumentation. Information från Läkemedelsverket 2007;6:9-57
23. Pain Proposal. Improving the current and future management of chronic pain. A European Consensus Report 2010. http://www.pfizer.se/Sites/PfizerSE/ Templates/Extension-3120.aspx?NewsItemID=23925. Accessed April 2010
24. Pain Proposal. Förbättrad handläggning av lå ngvarig smärta - idag och i framtiden. Swedish report 2010. http://www.pfizer.se/ Sites/PfizerSE/ Templates/Extension-3120.aspx?NewsItemID=23925. Acccessed April 2010
25. Turk DC. Clinical effectiveness of treatments for patients with chronic pain. Clin J Pain 2002;18:355-65
26. Gordon J, Lister S, Prettyjohns M, et al. A cost-utility study of the use of pregabalin in treatment-refractory neuropathic pain. J Med Econ 2012;15:207-18
27. Scottish Medicines Consortium (SMC). Advice: ''Pregabalin 25mg, 50mg, 75mg, 100mg, 150mg, 200mg and 300mg capsules (Lyrica-)'' No. (157/ 05) Pfizer Ltd. 2009. http://www.scottishmedicines.org.uk/SMC-Advice/ Advice/157-05- Pregabalin-Lyrica-/pregabalin-Lyrica. Accessed April 2010
28. Tandvå rds - och läkemedelsförmå nsverket (TLV) - In English. http:// www.tlv.se/in-english/. Accessed April 2010
29. Annemans L, Caekelbergh K, Morlion B, et al. A cost-utility analysis of pregabalin in the management of peripheral neuropathic pain. Acta Clinica Belgica 2008;63:170-8
30. Rodriguez MJ, Diaz S, Vera-Llonch M, et al. Cost-effectiveness analysis of pregabalin versus gabapentin in the management of neuropathic pain due to diabetic polyneuropathy or post-herpetic neuralgia. Curr Med Res Opin 2007;23:2585-96
31. Tarride JE, Gordon A, Vera-Llonch M, et al. Cost-effectiveness of pregabalin for the management of neuropathic pain associated with diabetic peripheral neuropathy and postherpetic neuralgia: a Canadian perspective. Clin Therapeut 2006;28:1922-34
32. Smith KJ, Roberts MS. Sequential medication strategies for postherpetic neuralgia: a cost-effectiveness analysis. J Pain 2007;8:396-404
33. Dworkin RH, Corbin AE, Young JP, et al. Pregabalin for the treatment of postherpetic neuralgia: a randomized, placebo controlled trial. Neurology 2003;60:1274-83
34. Edling A, Stenberg AM. General guidelines for economic evaluations from the Pharmaceutical Benefits Board. Solna, Sweden: Pharmaceutical Benefits Board 2003
35. EuroQol. http://www.euroqol.org/eq-5d/what-is-eq-5d/how-to-use-eq-5d/ descriptive-system.html. Accessed April 2010
36. Dolan P. Modeling valuations for EuroQol Health States. Med Care 1997;35:1095-108
37. Tandvå rds - och läkemedelsförmå nsverket (TLV). Product price database. http://www.tlv.se/. Accessed April 2010
38. Region Skå nes Prislista. Regionala Priser och Ersättningar för Södra Sjukvå rdsregionen. 2008. http://www.skane.se/sv/ Webbplatser/Sodraregionvardsnamnden/ PriserAvtal/Prislistorforegaende-ar/ Regionala-priser-ochersattningar- for-Sodrasjukvardsregionen-2008/ Accessed April 2010
39. Myrén K-J, Löfroth E, Sandelin R. Cost impact from initiating pregabalin treatment in patients with refractory neuropathic pain. Poster presented at ISPOR in Prague, 2010
40. Norrefalk Jr. Outcome of an 8-week multiprofessional work related rehabilitation programme for patients suffering from persistent musculoskeletalrelated pain. PhD Thesis. Department of Public Health Sciences, Karolinska Institutet: Stockholm; 2006. ISBN 91-7140-961-0
41. Norrefalk JR, Ekholm K, Linder J, et al. Evaluation of a multiprofessional rehabilitation programme for persistent muscuoskeletal-related pain: economic benefits of return to work. J Rehabil Med 2008;40:15-22
42. Norrefalk Jr. Ekonomisk utvärdering av multiprofessionell rehabilitering av patienter med lå ngvariga smärttillstå nd. En win-win-win situation för patient arbetsgivare och samhälle. Incitament 2008;1:27-30
43. Navarro A, Saldana MT, Perez C, et al. Patient-reported outcomes in subjects with neuropathic pain recieving pregabalin: evidence from medical practice in primary care settings. Pain Med 2010;11:719-31